Rockland Immunochemicals acquired the Epi-Plus® antibody product line from 21st Century Biochemicals. Epi-Plus antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP). The company will market the Epi-Plus product line on its e-commerce website and through its existing global distribution network.
"The acquisition of the Epi-Plus product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, president and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."
Research in epigenetics has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 billion in 2012 and is expected to reach $8 billion by 2017, a five-year CAGR of 25%.